JUNSHI BIO (01877) surged over 4%, reaching HK$26.06 by the time of writing, with a trading volume of HK$59.43 million.

On October 28, the company announced its financial results for the first three quarters of 2025. Revenue reached RMB 1.806 billion, up 42.06% year-on-year, while net loss attributable to shareholders narrowed by 35.7% to RMB 596 million. Basic loss per share stood at RMB 0.60.

The revenue growth was primarily driven by increased sales of commercialized drugs, with core product Toripalimab (brand name: Tuoyi®/LOQTORZI®, product code: JS001) generating domestic sales of approximately RMB 1.495 billion, up around 40% YoY.

The company has implemented cost-control measures and resource optimization under its "efficiency enhancement and shareholder return" initiative, significantly reducing losses compared to the same period last year.

As of the reporting period, JUNSHI BIO held cash and tradable financial assets totaling RMB 3.27 billion, indicating ample liquidity.